Literature DB >> 34127865

Inverse electron demand Diels-Alder click chemistry for pretargeted PET imaging and radioimmunotherapy.

Samantha M Sarrett1,2, Outi Keinänen1,3,4, Eric J Dayts1, Guillaume Dewaele-Le Roi1,3,5, Cindy Rodriguez1,5, Kathryn E Carnazza6, Brian M Zeglis7,8,9,10,11.   

Abstract

Radiolabeled antibodies have shown promise as tools for both the nuclear imaging and endoradiotherapy of cancer, but the protracted circulation time of radioimmunoconjugates can lead to high radiation doses to healthy tissues. To circumvent this issue, we have developed an approach to positron emission tomography (PET) imaging and radioimmunotherapy (RIT) predicated on radiolabeling the antibody after it has reached its target within the body. This in vivo pretargeting strategy is based on the rapid and bio-orthogonal inverse electron demand Diels-Alder reaction between tetrazine (Tz) and trans-cyclooctene (TCO). Pretargeted PET imaging and RIT using TCO-modified antibodies in conjunction with Tz-bearing radioligands produce high activity concentrations in target tissues as well as reduced radiation doses to healthy organs compared to directly labeled radioimmunoconjugates. Herein, we describe how to prepare a TCO-modified antibody (humanized A33-TCO) as well as how to synthesize two Tz-bearing radioligands: one labeled with the positron-emitting radiometal copper-64 ([64Cu]Cu-SarAr-Tz) and one labeled with the β-emitting radiolanthanide lutetium-177 ([177Lu]Lu-DOTA-PEG7-Tz). We also provide a detailed description of pretargeted PET and pretargeted RIT experiments in a murine model of human colorectal carcinoma. Proper training in both radiation safety and the handling of laboratory mice is required for the successful execution of this protocol.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34127865      PMCID: PMC8917728          DOI: 10.1038/s41596-021-00540-2

Source DB:  PubMed          Journal:  Nat Protoc        ISSN: 1750-2799            Impact factor:   13.491


  63 in total

1.  Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET.

Authors:  Iris Verel; Gerard W M Visser; Otto C Boerman; Julliette E M van Eerd; Ron Finn; Ronald Boellaard; Maria J W D Vosjan; Marijke Stigter-van Walsum; Gordon B Snow; Guus A M S van Dongen
Journal:  Cancer Biother Radiopharm       Date:  2003-08       Impact factor: 3.099

2.  A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer.

Authors:  Neeta Pandit-Taskar; Joseph A O'Donoghue; Jeremy C Durack; Serge K Lyashchenko; Sarah M Cheal; Volkan Beylergil; Robert A Lefkowitz; Jorge A Carrasquillo; Danny F Martinez; Alex Mak Fung; Stephen B Solomon; Mithat Gönen; Glenn Heller; Massimo Loda; David M Nanus; Scott T Tagawa; Jarett L Feldman; Joseph R Osborne; Jason S Lewis; Victor E Reuter; Wolfgang A Weber; Neil H Bander; Howard I Scher; Steven M Larson; Michael J Morris
Journal:  Clin Cancer Res       Date:  2015-07-14       Impact factor: 12.531

Review 3.  PET imaging with ⁸⁹Zr: from radiochemistry to the clinic.

Authors:  Melissa A Deri; Brian M Zeglis; Lynn C Francesconi; Jason S Lewis
Journal:  Nucl Med Biol       Date:  2012-09-19       Impact factor: 2.408

4.  Investigations of avidin and biotin for imaging applications.

Authors:  D J Hnatowich; F Virzi; M Rusckowski
Journal:  J Nucl Med       Date:  1987-08       Impact factor: 10.057

5.  PET imaging of zirconium-89 labelled cetuximab: A phase I trial in patients with head and neck and lung cancer.

Authors:  Judith van Loon; Aniek J G Even; Hugo J W L Aerts; Michel Öllers; Frank Hoebers; Wouter van Elmpt; Ludwig Dubois; Anne-Marie C Dingemans; Roy I Lalisang; Pascal Kempers; Boudewijn Brans; Véronique Winnepenninckx; Ernst-Jan Speel; Eric Thunnissen; Kim M Smits; Ronald Boellaard; Danielle J Vugts; Dirk De Ruysscher; Philippe Lambin
Journal:  Radiother Oncol       Date:  2016-12-21       Impact factor: 6.280

6.  Underscoring the influence of inorganic chemistry on nuclear imaging with radiometals.

Authors:  Brian M Zeglis; Jacob L Houghton; Michael J Evans; Nerissa Viola-Villegas; Jason S Lewis
Journal:  Inorg Chem       Date:  2013-12-06       Impact factor: 5.165

Review 7.  Optimization of radioimmunotherapy of solid tumors: biological impediments and their modulation.

Authors:  Maneesh Jain; Ganesh Venkatraman; Surinder K Batra
Journal:  Clin Cancer Res       Date:  2007-02-19       Impact factor: 12.531

8.  Phase 1 radioimmunotherapy study with lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma.

Authors:  Alexander B Stillebroer; Otto C Boerman; Ingrid M E Desar; Marije J Boers-Sonderen; Carla M L van Herpen; Johannes F Langenhuijsen; Peter M Smith-Jones; Egbert Oosterwijk; Wim J G Oyen; Peter F A Mulders
Journal:  Eur Urol       Date:  2012-08-21       Impact factor: 20.096

9.  Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-Ommaya 131-I-3F8.

Authors:  Kim Kramer; John L Humm; Mark M Souweidane; Pat B Zanzonico; Ira J Dunkel; William L Gerald; Yasmin Khakoo; Samuel D Yeh; Henry W Yeung; Ronald D Finn; Suzanne L Wolden; Steven M Larson; Nai-Kong V Cheung
Journal:  J Clin Oncol       Date:  2007-12-01       Impact factor: 44.544

10.  Site-specific antibody fragment conjugates for targeted imaging.

Authors:  Robert Maloney; Zakey Yusuf Buuh; Yue Zhao; Rongsheng E Wang
Journal:  Methods Enzymol       Date:  2020-03-31       Impact factor: 1.600

View more
  1 in total

Review 1.  Application of positron emission tomography in psychiatry-methodological developments and future directions.

Authors:  Simon Cervenka; Andreas Frick; Robert Bodén; Mark Lubberink
Journal:  Transl Psychiatry       Date:  2022-06-14       Impact factor: 7.989

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.